Form DEF 14A ATYR PHARMA For: 26 March
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
aTyr Pharma Inc (ATYR)
Assess today's live aTyr Pharma Inc (ATYR) share price, performance and insights using our live NASDAQ: ATYR stock exchange data.
Analyse the historical data and aTyr Pharma Inc share price performance charts on this page. Our technical summary section provides analysis on aTyr Pharma share price buy/sell indicators using real-time data (or discuss the aTyr Pharma (ATYR) stock price today with other investors in the aTyr Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ATYR share price (ISIN: US0021202025) to enhance your trading decisions with our free investment tools and resources.
What Is the aTyr Pharma Inc Share Price Today?
The aTyr Pharma share price today is 0.752.
What Is the Stock Symbol for aTyr Pharma Inc
The stock symbol (or 'ticker') for Life Technologies Corporation is "ATYR."
What Stock Exchange Does aTyr Pharma Inc Trade On?
Life Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether Life Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and aTyr Pharma Inc share price performance charts on this page. Our technical summary section provides analysis on aTyr Pharma share price buy/sell indicators using real-time data (or discuss the aTyr Pharma (ATYR) stock price today with other investors in the aTyr Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ATYR share price (ISIN: US0021202025) to enhance your trading decisions with our free investment tools and resources.
What Is the aTyr Pharma Inc Share Price Today?
The aTyr Pharma share price today is 0.752.
What Is the Stock Symbol for aTyr Pharma Inc
The stock symbol (or 'ticker') for Life Technologies Corporation is "ATYR."
What Stock Exchange Does aTyr Pharma Inc Trade On?
Life Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether Life Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.750
0.793
52 wk Range
0.640
7.290
ATYR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7500.793
52 wk Range
0.6407.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATYR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
4.357
Upside
+479.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form PRE 14A ATYR PHARMA For: 12 March
- Investing.com
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form DEF 14A ATYR PHARMA For: 26 March
- Investing.com
- Form PRE 14A ATYR PHARMA For: 12 March
- Investing.com
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma Inc SWOT Analysis
Efzofitimod's Promise | Explore aTyr Pharma's lead candidate for pulmonary sarcoidosis, currently in Phase 3 trials, with potential to revolutionize interstitial lung disease treatment |
Market Opportunity | Delve into the substantial market for pulmonary sarcoidosis treatments, with an estimated 200,000 patients in the US alone seeking alternatives to corticosteroids |
Financial Outlook | Uncover aTyr's solid financial position with $87.3M in cash, supporting ongoing clinical programs. Analyst price targets range from $11 to $16 per share |
Future Catalysts | Anticipate key data readouts in 2025, including proof-of-concept for SSc-ILD and Phase 3 results for pulmonary sarcoidosis, potentially transforming aTyr's market position |
aTyr Pharma Inc Earnings Call Summary for Q4/2024
- aTyr Pharma Q4 2024 EPS of -$0.18 beat expectations of -$0.23, with $75.1M cash on hand and $200K revenue from collaborations
- Phase III EFSOFIT study enrollment completed; top-line data expected Q3 2024 for lead candidate Esofitamod in pulmonary sarcoidosis
- Stock rose 12.39% in regular trading but fell 9.77% after hours; analysts maintain strong buy consensus with $9-$35 price targets
- R&D expenses of $54.4M reflect ongoing investment in therapeutic candidates; company exploring additional indications and pipeline development
- CEO Sanjay Shukla emphasized scientific advancements and potential impact across medical fields; EFSOFIT study maintains 90% statistical power
Last Updated: 13/03/2025, 22:18
Read Full TranscriptCompare ATYR to Peers and Sector
Metrics to compare | ATYR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATYRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −15.3x | −0.4x | |
PEG Ratio | −0.13 | −0.02 | 0.00 | |
Price/Book | 1.1x | 4.9x | 2.6x | |
Price / LTM Sales | 388.1x | 12.2x | 3.1x | |
Upside (Analyst Target) | 33.0% | 86.5% | 56.0% | |
Fair Value Upside | Unlock | 0.7% | 9.0% | Unlock |
Analyst Ratings
3 Buy
6 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 4.357
(+479.41% Upside)
Earnings
Latest Release
05/03/2026
EPS / Forecast
-0.14 / -0.18
Revenue / Forecast
-- / 25K
People Also Watch
FAQ
What Is the aTyr Pharma (ATYR) Share Price Today?
The aTyr Pharma stock price today is 0.752 USD.
What Stock Exchange Does aTyr Pharma (ATYR) Trade On?
aTyr Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for aTyr Pharma?
The stock symbol (also called a 'ticker') for aTyr Pharma is "ATYR."
What Is the Current aTyr Pharma Market Cap?
As of today, aTyr Pharma market cap is 73.730M USD.
What Is aTyr Pharma's (ATYR) Earnings Per Share (TTM)?
The aTyr Pharma EPS is currently -0.797 (Trailing Twelve Months).
When Is the Next aTyr Pharma Earnings Date?
aTyr Pharma's next earnings report will be released on 13/05/2026.
Is ATYR a Buy or Sell From a Technical Analyst Perspective?
Based on today's aTyr Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has aTyr Pharma Stock Split?
aTyr Pharma has split 1 times. (See the ATYR stock split history page for full effective split date and price information.)
How Many Employees Does aTyr Pharma Have?
aTyr Pharma has 59 employees.
What is the current trading status of aTyr Pharma (ATYR)?
As of 29/03/2026, aTyr Pharma (ATYR) is trading at a price of 0.752 USD, with a previous close of 0.793 USD. The stock has fluctuated within a day range of 0.750 USD to 0.793 USD, while its 52-week range spans from 0.640 USD to 7.290 USD.
What Is aTyr Pharma (ATYR) Price Target According to Analysts?
The average 12-month price target for aTyr Pharma is 4.357 USD, with a high estimate of 20 USD and a low estimate of 1 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +479.41% Upside potential.
What Is the ATYR Premarket Price?
ATYR's last pre-market stock price is 0.782 USD. The pre-market share volume is 2,910.000, and the stock has decreased by -0.011, or -1.390%.
What Is the ATYR After Hours Price?
ATYR's last after hours stock price is 0.759 USD, the stock has decreased by 0.007, or 0.940%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.